Imlygic (talimogene laherparepvec) for the Treatment of Cutaneous, Subcutaneous and Nodal Lesions

Developed by Amgen, Imlygic (talimogene laherparepvec) is the first injectable formulation of altered herpes simplex virus type 1 for the treatment of cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrence after initial surger…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news